Top of page

Experience

To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.

Filters

Abcam $180 million U.S. IPO of ADSs
Davis Polk advised the representatives of the several underwriters in connection with Abcam plc’s $180 million U.S. initial public offering of 10,287,000 American depositary shares…
Aligos Therapeutics $150 million IPO
Davis Polk advised  the representatives of the several underwriters in connection with the $150 million initial public offering of 10,000,000 shares of common stock of Aligos…
Eargo $165.2 million IPO
Davis Polk advised the representatives of the several underwriters in connection with an initial public offering of 9,029,629 shares of common stock of Eargo, Inc. at $18.00 per share …
Royalty Pharma $728 million secondary offering
Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $728 million secondary offering of 17,343,037 of its Class A ordinary shares by certain selling…
Turmeric Acquisition $97.75 million IPO
Davis Polk advised the joint book-running managers in connection with the $97.75 million initial public offering of 9,775,000 units of Turmeric Acquisition Corp., which includes 1,275…
Smith+Nephew $1 billion notes offering
Davis Polk advised Smith & Nephew plc in connection with the establishment of a WKSI shelf and its debut SEC-registered shelf takedown of $1 billion aggregate principal amount of 2.032%…
Aziyo Biologics $50 million IPO
Davis Polk advised the representatives of the several underwriters in connection with the $50 million initial public offering of common stock by Aziyo Biologics, Inc. The common stock…
Back to top